Anti-Mouse CD16.2 Antibody (9E9) is an inhibitory antibody derived from Armenian hamster, targeting mouse CD16.2.This antibody can bind to mouse CD16.2, which is also known as FcγRIV (Fc receptor, IgG, low affinity IV).Anti-Mouse CD16.2 Antibody (9E9) can inhibit the expression and signaling of CD16.2 on the cell surface and block FcγRIV.This antibody is applicable to studies related to cancer, inflammation and immunology, including CT26 tumor models and pulmonary inflammation .

Anti-Mouse CD16.2 Antibody (9E9) (10 μg/mL) inhibits IgE immune complex-induced TNF-α secretion in MH-S cells [1].

Anti-Mouse CD16.2 Antibody (9E9) (administered intravenously 1 day before harvesting thioglycolate-induced macrophages) inhibits approximately 25% of macrophage TNF-α secretion in hFcεRITg mice [1].
Anti-Mouse CD16.2 Antibody (9E9) (200 μg, intraperitoneal injection on days 0, 4, and 8) alleviates skin lesions in mice with bullous pemphigoid [2].
Anti-Mouse CD16.2 Antibody (9E9) (200 μg, intravenously 1 hour before anti-CTLA4 injection) prevents anti-CTLA4-mediated regulatory T cell depletion in CT26 tumor-bearing mice [3].

9E9

Mouse

Monoclonal

Unconjugated